Successful Tralokinumab Treatment for Hand and Foot Atopic Dermatitis in a Patient with Skin of Color: A Case Report

Main Article Content

Porcia Love
River Region Dermatology and Laser, Montgomery, AL, USA

Chloe J. Walker, MD, MHS
River Region Dermatology and Laser, Montgomery, AL, USA

Keywords

Atopic dermatitis, tralokinumab, skin of color, hand-foot dermatitis

Abstract

Atopic dermatitis (AD) is a common chronic inflammatory skin condition that disproportionately affects skin of color patients. New targeted biological therapies such as tralokinumab are available for the management of AD, but real-world evidence of their clinical effectiveness in skin of color patients is limited, particularly in patients with difficult-to-treat hand and foot involvement. In this report, we present a case of recalcitrant atopic dermatitis with hand-foot involvement in a skin of color patient successfully treated with tralokinumab.

References

1. Sangha AM. Dermatological Conditions in SKIN OF COLOR—: Managing Atopic Dermatitis. J Clin Aesthet Dermatol. 2021;14(3 Suppl 1):S20-S22.

2. Fu T, Keiser E, Linos E, et al. Eczema and Sensitization to Common Allergens in the United States: A Multiethnic, Population-Based Study. Pediatric Dermatology. 2014;31(1):21-26. doi:10.1111/pde.12237

3. Duggan S. Tralokinumab: First Approval. Drugs. 2021;81(14):1657-1663. doi:10.1007/s40265-021-01583-1

4. Kelly KA, Perche PO, Feldman SR. Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data. CCID. 2022;15:1037-1043. doi:10.2147/CCID.S267217

5. Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. doi:10.1111/bjd.19574

6. Simpson EL, Silverberg JI, Worm M, et al. Dupilumab treatment improves signs, symptoms, quality of life and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. Published online February 1, 2024. doi:10.1016/j.jaad.2023.12.066

7. Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046-1055. doi:10.1111/jdv.18849

8. Li Y, Xiao J, Sun Y, Fang H, Qiao J. Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review. J Asthma Allergy. 2023;16:1-8. doi:10.2147/JAA.S399340

9. Deng L, Luo Y, An B, Su M, Sang H, Liu F. Recalcitrant Palmar-Plantar Atopic Dermatitis Successfully Treated with Dupilumab: A Case Series. Clin Cosmet Investig Dermatol. 2022;15:2421-2426. doi:10.2147/CCID.S383327

10. Murase JE, Chovatiya R, Strowd L, et al. 381 Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis. British journal of dermatology (1951). 2023;188(Supplement_3). doi:10.1093/bjd/ljad162.009

11. Kamphuis E, Loman L, Han HL, Romeijn GLE, Politiek K, Schuttelaar MLA. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis. 2023;88(5):351-362. doi:10.1111/cod.14276

12. Simpson EL, Rahawi K, Hu X, et al. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials. Journal of the European Academy of Dermatology and Venereology. 2023;37(9):1863-1870. doi:10.1111/jdv.19194

Article Sidebar

PDF
Published
Jul 23, 2024
DOI https://doi.org/10.25251/skin.8.4.20

Article Details

How to Cite
Love, P., & Walker, C. . (2024). Successful Tralokinumab Treatment for Hand and Foot Atopic Dermatitis in a Patient with Skin of Color: A Case Report. SKIN The Journal of Cutaneous Medicine, 8(4), 1752–1756. https://doi.org/10.25251/skin.8.4.20
Issue
Vol. 8 No. 4 (2024): July 2024 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.